238
Views
12
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Mutations in ABL kinase domain are associated with inferior progression-free survival

, , &
Pages 1072-1078 | Received 13 Nov 2009, Accepted 23 Feb 2010, Published online: 01 Apr 2010
 

Abstract

Imatinib mesylate is currently the drug of choice for all phases of chronic myeloid leukemia (CML). Despite the initial high rates of hematological and cytogenetic responses, many patients develop resistance. We prospectively studied 40 patients with CML with primary cytogenetic resistance to imatinib mesylate. A semi-nested reverse transcriptase-PCR approach was used for amplification of the ABL kinase domain, which was then subjected to direct sequencing for the detection of point mutations. Expression of BCR–ABL transcripts was quantified using the real-time Taqman assay, and BCR–ABL gene amplification was detected using fluorescence in situ hybridization. Twelve different point mutations were detected in 18/40 (45%) patients. Five patients had mutations in the P-loop region and 13 had mutations in other regions of the BCR–ABL kinase domain. Progression-free survival at 2 years was inferior for patients with mutations compared to those without mutations (72% vs. 95%, p < 0.0045). The BCR–ABL fusion gene was over-expressed in five patients (5/18); the mean BCR–ABL/ABL ratio was 75.38 vs. 28.72 for imatinib responders, p < 0.001. Amplification of the BCR–ABL fusion gene was detected in 4/40 (10%) patients. Point mutation was the major mechanism of primary cytogenetic resistance to imatinib mesylate in the present study. Patients with mutations had inferior progression-free survival compared to those without mutations. Regular monitoring for the presence of point mutations in the ABL kinase region may identify such patients early, with an opportunity to intervene.

Acknowledgements

We are grateful to the Max Foundation of India for providing free Gleevec for patients in this study.

Declaration of interest: This work was supported by a research grant from the Terry Fox Foundation, Canada. One of the authors (P.S.) was supported by the Council of Scientific Industrial Research (CSIR), Government of India, New Delhi, India.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.